Bio-Techne (TECH) Total Non-Current Liabilities (2014 - 2026)
Bio-Techne (TECH) recorded quarterly Total Non-Current Liabilities of $443.6 million in Q1 2026, down 9.21% quarter-over-quarter from $488.6 million in Q4 2025, and down 27.34% on a YoY basis from $610.6 million in Q1 2025.
Bio-Techne (TECH) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Bio-Techne's Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $443.6 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 27.34% year-over-year to $443.6 million; the TTM figure through Mar 2026 stood at $443.6 million (down 27.34% YoY), while the FY2025 annual figure was $612.0 million, down 1.59% from the prior year.
- Total Non-Current Liabilities was $443.6 million for Q1 2026 at Bio-Techne, down from $488.6 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $749.8 million in Q4 2023 to a low of $443.6 million in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $606.2 million across 5 years, with a median of $588.1 million in 2022.
- The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities soared 41.67% in 2023, then dropped 27.34% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $529.3 million in 2022, then soared by 41.67% to $749.8 million in 2023, then slipped by 22.57% to $580.6 million in 2024, then retreated by 15.84% to $488.6 million in 2025, then decreased by 9.21% to $443.6 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $443.6 million (Q1 2026), $488.6 million (Q4 2025), and $536.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Bio-Techne | 9.04 Bn | 8.83 Bn | 208.29 Mn | 443.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 443.63 Mn |
| Dec 31, 2025 | 488.63 Mn |
| Sep 30, 2025 | 536.52 Mn |
| Jun 30, 2025 | 611.98 Mn |
| Mar 31, 2025 | 610.58 Mn |
| Dec 31, 2024 | 580.60 Mn |
| Sep 30, 2024 | 577.58 Mn |
| Jun 30, 2024 | 621.86 Mn |
| Mar 31, 2024 | 695.24 Mn |
| Dec 31, 2023 | 749.83 Mn |
| Sep 30, 2023 | 748.22 Mn |
| Jun 30, 2023 | 661.26 Mn |
| Mar 31, 2023 | 699.04 Mn |
| Dec 31, 2022 | 529.30 Mn |
| Sep 30, 2022 | 588.07 Mn |
| Jun 30, 2022 | 581.56 Mn |
| Mar 31, 2022 | 581.77 Mn |
| Dec 31, 2021 | 590.57 Mn |
| Sep 30, 2021 | 605.63 Mn |
| Jun 30, 2021 | 673.42 Mn |